報價延遲最少15分鐘:2026/03/30 11:24 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.545 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.57/-0.25
|
|
企業價值
233.83M
|
| 資產負債 |
|
每股賬面淨值
1.84
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
18.67M
|
|
每股收益
0.46
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. |
